Posted by Michael Wonder on 23 Jan 2023
Cadrenal Therapeutics granted FDA fast track designation for tecarfarin for prevention of systemic thromboembolism of cardiac origin in patients with end stage renal disease and atrial fibrillation
23 January 2023 - Cadrenal Therapeutics announced today that the US FDA has granted a fast track designation to tecarfarin for the prevention of systemic thromboembolism of cardiac origin in patients with end stage renal disease and atrial fibrillation.
The FDA had previously granted an orphan drug designation for tecarfarin.
